Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02581137
PHASE2

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

Sponsor: National Cancer Institute (NCI)

View on ClinicalTrials.gov

Summary

This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.

Official title: M4OC-Prevent: Metformin for Oral Cancer Prevention

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

26

Start Date

2016-06-10

Completion Date

2026-12-19

Last Updated

2026-04-09

Healthy Volunteers

No

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Metformin Hydrochloride

Given PO

Locations (4)

UC San Diego Medical Center - Hillcrest

San Diego, California, United States

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, United States

BC Cancer Research Centre

Vancouver, British Columbia, Canada

University of British Columbia Hospital

Vancouver, British Columbia, Canada